ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference

Rhea-AI Summary

ImmunoGen, Inc. (NASDAQ: IMGN) announced that CFO Susan Altschuller will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 am ET. The presentation will be available via webcast on the company's website, with a replay accessible afterward. ImmunoGen focuses on developing innovative antibody-drug conjugates (ADCs) to enhance cancer treatment outcomes, demonstrating a commitment to improving patient experiences with targeted therapies.

Positive

• Participation in H.C. Wainwright Global Investment Conference highlights investor interest.
• Commitment to developing next-generation ADCs may improve treatment outcomes for cancer patients.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will present at the upcoming H.C. Wainwright Global Investment Conference. The presentation will be available on May 24, 2022 at 7:00am ET.

A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com. Following the webcast, a replay will be available at the same location.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220510006139/en/

INVESTOR RELATIONS AND MEDIA

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

FAQ

What is the date and time of ImmunoGen's presentation at the H.C. Wainwright Conference?

ImmunoGen's presentation is scheduled for May 24, 2022, at 7:00 am ET.

Where can I access the webcast of ImmunoGen's conference presentation?

The webcast can be accessed in the 'Investors and Media' section of ImmunoGen's website.

What is the focus of ImmunoGen's research and development?

ImmunoGen is focused on developing antibody-drug conjugates (ADCs) to improve cancer treatment outcomes.

What stock symbol does ImmunoGen operate under?

ImmunoGen operates under the stock symbol IMGN on NASDAQ.